Merlin: The wizard requires protein stability to function as a tumor suppressor

Biochimica et Biophysica Acta - Reviews on Cancer

Volumn 1826, Issue 2, 2012, Pages 400-406

  Morrow, K Adam ^a   Shevde, Lalita A ^b,c  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Merlin; Neurofibromatosis; NF2; Stability; Tumor microenvironment

Indexed keywords

MERLIN; MESSENGER RNA;

EPIGENETICS; GENE EXPRESSION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STABILITY; REVIEW; RNA STABILITY; RNA TRANSCRIPTION; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; NEUROFIBROMIN 2; PROTO-ONCOGENE PROTEINS C-AKT; RNA STABILITY; TUMOR SUPPRESSOR PROTEINS;

EID: 84864063110     PISSN: 0304419X     EISSN: 18792561     Source Type: Journal    
DOI: 10.1016/j.bbcan.2012.06.005     Document Type: Review

References (108)

1. Evans D.G., Howard E., Giblin C., Clancy T., Spencer H., Huson S.M., Lalloo F. Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am. J. Med. Genet. A 2010, 152A:327-332.
2. Scoles D.R. The Merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim. Biophys. Acta 2008, 1785:32-54.
3. Irving R.M., Moffat D.A., Hardy D.G., Barton D.E., Xuereb J.H., Maher E.R. Somatic NF2 gene mutations in familial and non-familial vestibular schwannoma. Hum. Mol. Genet. 1994, 3:347-350.
4. Ruttledge M.H., Sarrazin J., Rangaratnam S., Phelan C.M., Twist E., Merel P., Delattre O., Thomas G., Nordenskjold M., Collins V.P., et al. Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas. Nat. Genet. 1994, 6:180-184.
5. Jacoby L.B., MacCollin M., Louis D.N., Mohney T., Rubio M.P., Pulaski K., Trofatter J.A., Kley N., Seizinger B., Ramesh V., et al. Exon scanning for mutation of the NF2 gene in schwannomas. Hum. Mol. Genet. 1994, 3:413-419.
6. Ueki K., Wen-Bin C., Narita Y., Asai A., Kirino T. Tight association of loss of Merlin expression with loss of heterozygosity at chromosome 22q in sporadic meningiomas. Cancer Res. 1999, 59:5995-5998.
7. Sainz J., Huynh D.P., Figueroa K., Ragge N.K., Baser M.E., Pulst S.M. Mutations of the neurofibromatosis type 2 gene and lack of the gene product in vestibular schwannomas. Hum. Mol. Genet. 1994, 3:885-891.
8. Bianchi A.B., Mitsunaga S.I., Cheng J.Q., Klein W.M., Jhanwar S.C., Seizinger B., Kley N., Klein-Szanto A.J., Testa J.R. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:10854-10858.
9. Sekido Y., Pass H.I., Bader S., Mew D.J., Christman M.F., Gazdar A.F., Minna J.D. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 1995, 55:1227-1231.
10. Cheng J.Q., Lee W.C., Klein M.A., Cheng G.Z., Jhanwar S.C., Testa J.R. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999, 24:238-242.
11. Rustgi A.K., Xu L., Pinney D., Sterner C., Beauchamp R., Schmidt S., Gusella J.F., Ramesh V. Neurofibromatosis 2 gene in human colorectal cancer. Cancer Genet. Cytogenet. 1995, 84:24-26.
12. Horiguchi A., Zheng R., Shen R., Nanus D.M. Inactivation of the NF2 tumor suppressor protein Merlin in DU145 prostate cancer cells. Prostate 2008, 68:975-984.
13. Bianchi A.B., Hara T., Ramesh V., Gao J., Klein-Szanto A.J., Morin F., Menon A.G., Trofatter J.A., Gusella J.F., Seizinger B.R., et al. Mutations in transcript isoforms of the neurofibromatosis 2 gene in multiple human tumour types. Nat. Genet. 1994, 6:185-192.
14. Rouleau G.A., Merel P., Lutchman M., Sanson M., Zucman J., Marineau C., Hoang-Xuan K., Demczuk S., Desmaze C., Plougastel B., et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993, 363:515-521.
15. Trofatter J.A., MacCollin M.M., Rutter J.L., Murrell J.R., Duyao M.P., Parry D.M., Eldridge R., Kley N., Menon A.G., Pulaski K., et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993, 75:826.
16. Bretscher A., Chambers D., Nguyen R., Reczek D. ERM-Merlin and EBP50 protein families in plasma membrane organization and function. Annu. Rev. Cell Dev. Biol. 2000, 16:113-143.
17. McClatchey A.I., Saotome I., Ramesh V., Gusella J.F., Jacks T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes Dev. 1997, 11:1253-1265.
18. Giovannini M., Robanus-Maandag E., van der Valk M., Niwa-Kawakita M., Abramowski V., Goutebroze L., Woodruff J.M., Berns A., Thomas G. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev. 2000, 14:1617-1630.
19. McClatchey A.I., Saotome I., Mercer K., Crowley D., Gusella J.F., Bronson R.T., Jacks T. Mice heterozygous for a mutation at the Nf2 tumor suppressor locus develop a range of highly metastatic tumors. Genes Dev. 1998, 12:1121-1133.
20. Tikoo A., Varga M., Ramesh V., Gusella J., Maruta H. An anti-Ras function of neurofibromatosis type 2 gene product (NF2/Merlin). J. Biol. Chem. 1994, 269:23387-23390.
21. Morrison H., Sperka T., Manent J., Giovannini M., Ponta H., Herrlich P. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 2007, 67:520-527.
22. Ryu C.H., Kim S.W., Lee K.H., Lee J.Y., Kim H., Lee W.K., Choi B.H., Lim Y., Kim Y.H., Hwang T.K., Jun T.Y., Rha H.K. The Merlin tumor suppressor interacts with Ral guanine nucleotide dissociation stimulator and inhibits its activity. Oncogene 2005, 24:5355-5364.
23. Kissil J.L., Wilker E.W., Johnson K.C., Eckman M.S., Yaffe M.B., Jacks T. Merlin, the product of the Nf2 tumor suppressor gene, is an inhibitor of the p21-activated kinase, Pak1. Mol. Cell 2003, 12:841-849.
24. Hirokawa Y., Tikoo A., Huynh J., Utermark T., Hanemann C.O., Giovannini M., Xiao G.H., Testa J.R., Wood J., Maruta H. A clue to the therapy of neurofibromatosis type 2: NF2/Merlin is a PAK1 inhibitor. Cancer J. 2004, 10:20-26.
25. Shaw R.J., Paez J.G., Curto M., Yaktine A., Pruitt W.M., Saotome I., O'Bryan J.P., Gupta V., Ratner N., Der C.J., Jacks T., McClatchey A.I. The Nf2 tumor suppressor, Merlin, functions in Rac-dependent signaling. Dev. Cell 2001, 1:63-72.
26. Yi C., Troutman S., Fera D., Stemmer-Rachamimov A., Avila J.L., Christian N., Persson N.L., Shimono A., Speicher D.W., Marmorstein R., Holmgren L., Kissil J.L. A tight junction-associated Merlin-angiomotin complex mediates Merlin's regulation of mitogenic signaling and tumor suppressive functions. Cancer Cell 2011, 19:527-540.
27. Sherman L., Xu H.M., Geist R.T., Saporito-Irwin S., Howells N., Ponta H., Herrlich P., Gutmann D.H. Interdomain binding mediates tumor growth suppression by the NF2 gene product. Oncogene 1997, 15:2505-2509.
28. Morrison H., Sherman L.S., Legg J., Banine F., Isacke C., Haipek C.A., Gutmann D.H., Ponta H., Herrlich P. The NF2 tumor suppressor gene product, Merlin, mediates contact inhibition of growth through interactions with CD44. Genes Dev. 2001, 15:968-980.
29. Ikeda K., Saeki Y., Gonzalez-Agosti C., Ramesh V., Chiocca E.A. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of Merlin due to vector-mediated gene transfer. J. Neurosurg. 1999, 91:85-92.
30. Kim H., Kwak N.J., Lee J.Y., Choi B.H., Lim Y., Ko Y.J., Kim Y.H., Huh P.W., Lee K.H., Rha H.K., Wang Y.P. Merlin neutralizes the inhibitory effect of Mdm2 on p53. J. Biol. Chem. 2004, 279:7812-7818.
31. Xiao G.H., Gallagher R., Shetler J., Skele K., Altomare D.A., Pestell R.G., Jhanwar S., Testa J.R. The NF2 tumor suppressor gene product, Merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol. Cell. Biol. 2005, 25:2384-2394.
32. Hamaratoglu F., Willecke M., Kango-Singh M., Nolo R., Hyun E., Tao C., Jafar-Nejad H., Halder G. The tumour-suppressor genes NF2/Merlin and expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat. Cell Biol. 2006, 8:27-36.
33. Bai Y., Liu Y.J., Wang H., Xu Y., Stamenkovic I., Yu Q. Inhibition of the hyaluronan-CD44 interaction by Merlin contributes to the tumor-suppressor activity of Merlin. Oncogene 2007, 26:836-850.
34. Li W., Giancotti F.G. Merlin's tumor suppression linked to inhibition of the E3 ubiquitin ligase CRL4 (DCAF1). Cell Cycle 2010, 9:4433-4436.
35. Cooper J., Li W., You L., Schiavon G., Pepe-Caprio A., Zhou L., Ishii R., Giovannini M., Hanemann C.O., Long S.B., Erdjument-Bromage H., Zhou P., Tempst P., Giancotti F.G. Merlin/NF2 functions upstream of the nuclear E3 ubiquitin ligase CRL4DCAF1 to suppress oncogenic gene expression. Sci. Signal. 2011, 4:t6.
36. Curto M., Cole B.K., Lallemand D., Liu C.H., McClatchey A.I. Contact-dependent inhibition of EGFR signaling by Nf2/Merlin. J. Cell Biol. 2007, 177:893-903.
37. Cole B.K., Curto M., Chan A.W., McClatchey A.I. Localization to the cortical cytoskeleton is necessary for Nf2/Merlin-dependent epidermal growth factor receptor silencing. Mol. Cell. Biol. 2008, 28:1274-1284.
38. Plotkin S.R., Halpin C., McKenna M.J., Loeffler J.S., Batchelor T.T., Barker F.G. Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol. Neurotol. 2010, 31:1135-1143.
39. James M.F., Han S., Polizzano C., Plotkin S.R., Manning B.D., Stemmer-Rachamimov A.O., Gusella J.F., Ramesh V. NF2/Merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell. Biol. 2009, 29:4250-4261.
40. Neff B.A., Welling D.B., Akhmametyeva E., Chang L.S. The molecular biology of vestibular schwannomas: dissecting the pathogenic process at the molecular level. Otol. Neurotol. 2006, 27:197-208.
41. Sughrue M.E., Yeung A.H., Rutkowski M.J., Cheung S.W., Parsa A.T. Molecular biology of familial and sporadic vestibular schwannomas: implications for novel therapeutics. J. Neurosurg. 2011, 114:359-366.
42. Yoshiura K., Kanai Y., Ochiai A., Shimoyama Y., Sugimura T., Hirohashi S. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:7416-7419.
43. Merlo A., Herman J.G., Mao L., Lee D.J., Gabrielson E., Burger P.C., Baylin S.B., Sidransky D. 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1995, 1:686-692.
44. Herman J.G., Latif F., Weng Y., Lerman M.I., Zbar B., Liu S., Samid D., Duan D.S., Gnarra J.R., Linehan W.M., et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:9700-9704.
45. Kino T., Takeshima H., Nakao M., Nishi T., Yamamoto K., Kimura T., Saito Y., Kochi M., Kuratsu J., Saya H., Ushio Y. Identification of the cis-acting region in the NF2 gene promoter as a potential target for mutation and methylation-dependent silencing in schwannoma. Genes Cells 2001, 6:441-454.
46. Gonzalez-Gomez P., Bello M.J., Alonso M.E., Lomas J., Arjona D., Campos J.M., Vaquero J., Isla A., Lassaletta L., Gutierrez M., Sarasa J.L., Rey J.A. CpG island methylation in sporadic and neurofibromatis type 2-associated schwannomas. Clin. Cancer Res. 2003, 9:5601-5606.
47. Kullar P.J., Pearson D.M., Malley D.S., Collins V.P., Ichimura K. CpG island hypermethylation of the neurofibromatosis type 2 (NF2) gene is rare in sporadic vestibular schwannomas. Neuropathol. Appl. Neurobiol. 2010, 36:505-514.
48. van Tilborg A.A., Morolli B., Giphart-Gassler M., de Vries A., van Geenen D.A., Lurkin I., Kros J.M., Zwarthoff E.C. Lack of genetic and epigenetic changes in meningiomas without NF2 loss. J. Pathol. 2006, 208:564-573.
49. Hansson C.M., Buckley P.G., Grigelioniene G., Piotrowski A., Hellstrom A.R., Mantripragada K., Jarbo C., Mathiesen T., Dumanski J.P. Comprehensive genetic and epigenetic analysis of sporadic meningioma for macro-mutations on 22q and micro-mutations within the NF2 locus. BMC Genomics 2007, 8:16.
50. Alonso M.E., Bello M.J., Gonzalez-Gomez P., Arjona D., de Campos J.M., Gutierrez M., Rey J.A. Aberrant CpG island methylation of multiple genes in ependymal tumors. J. Neurooncol 2004, 67:159-165.
51. Vilborg A., Glahder J.A., Wilhelm M.T., Bersani C., Corcoran M., Mahmoudi S., Rosenstierne M., Grander D., Farnebo M., Norrild B., Wiman K.G. The p53 target Wig-1 regulates p53 mRNA stability through an AU-rich element. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:15756-15761.
52. Scoumanne A., Cho S.J., Zhang J., Chen X. The cyclin-dependent kinase inhibitor p21 is regulated by RNA-binding protein PCBP4 via mRNA stability. Nucleic Acids Res. 2011, 39:213-224.
53. Hoang-Xuan K., Merel P., Vega F., Hugot J.P., Cornu P., Delattre J.Y., Poisson M., Thomas G., Delattre O. Analysis of the NF2 tumor-suppressor gene and of chromosome 22 deletions in gliomas. Int. J. Cancer 1995, 60:478-481.
54. Jacoby L.B., MacCollin M., Parry D.M., Kluwe L., Lynch J., Jones D., Gusella J.F. Allelic expression of the NF2 gene in neurofibromatosis 2 and schwannomatosis. Neurogenetics 1999, 2:101-108.
55. Wellenreuther R., Waha A., Vogel Y., Lenartz D., Schramm J., Wiestler O.D., von Deimling A. Quantitative analysis of neurofibromatosis type 2 gene transcripts in meningiomas supports the concept of distinct molecular variants. Lab. Invest. 1997, 77:601-606.
56. Deguen B., Goutebroze L., Giovannini M., Boisson C., van der Neut R., Jaurand M.C., Thomas G. Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene. Int. J. Cancer 1998, 77:554-560.
57. Kanai Y., Tsuda H., Oda T., Sakamoto M., Hirohashi S. Analysis of the neurofibromatosis 2 gene in human breast and hepatocellular carcinomas. Jpn. J. Clin. Oncol. 1995, 25:1-4.
58. Arakawa H., Hayashi N., Nagase H., Ogawa M., Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum. Mol. Genet. 1994, 3:565-568.
59. Yaegashi S., Sachse R., Ohuchi N., Mori S., Sekiya T. Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers. Jpn. J. Cancer Res. 1995, 86:929-933.
60. Morrow K.A., Das S., Metge B.J., Ye K., Mulekar M.S., Tucker J.A., Samant R.S., Shevde L.A. Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation. J. Biol. Chem. 2011, 286:40376-40385.
61. Arpin M., Algrain M., Louvard D. Membrane-actin microfilament connections: an increasing diversity of players related to band 4.1. Curr. Opin. Cell Biol. 1994, 6:136-141.
62. Algrain M., Turunen O., Vaheri A., Louvard D., Arpin M. Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker. J. Cell Biol. 1993, 120:129-139.
63. Turunen O., Wahlstrom T., Vaheri A. Ezrin has a COOH-terminal actin-binding site that is conserved in the ezrin protein family. J. Cell Biol. 1994, 126:1445-1453.
64. Shimizu T., Seto A., Maita N., Hamada K., Tsukita S., Hakoshima T. Structural basis for neurofibromatosis type 2. Crystal structure of the Merlin FERM domain. J. Biol. Chem. 2002, 277:10332-10336.
65. Gronholm M., Sainio M., Zhao F., Heiska L., Vaheri A., Carpen O. Homotypic and heterotypic interaction of the neurofibromatosis 2 tumor suppressor protein Merlin and the ERM protein ezrin. J. Cell Sci. 1999, 112(Pt 6):895-904.
66. Pearson M.A., Reczek D., Bretscher A., Karplus P.A. Structure of the ERM protein moesin reveals the FERM domain fold masked by an extended actin binding tail domain. Cell 2000, 101:259-270.
67. Yogesha S.D., Sharff A.J., Giovannini M., Bricogne G., Izard T. Unfurling of the band 4.1, ezrin, radixin, moesin (FERM) domain of the Merlin tumor suppressor. Protein Sci. 2011, 20:2113-2120.
68. Jin H., Sperka T., Herrlich P., Morrison H. Tumorigenic transformation by CPI-17 through inhibition of a Merlin phosphatase. Nature 2006, 442:576-579.
69. Thurneysen C., Opitz I., Kurtz S., Weder W., Stahel R.A., Felley-Bosco E. Functional inactivation of NF2/Merlin in human mesothelioma. Lung Cancer 2009, 64:140-147.
70. Kissil J.L., Johnson K.C., Eckman M.S., Jacks T. Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on Merlin localization. J. Biol. Chem. 2002, 277:10394-10399.
71. Xiao G.H., Beeser A., Chernoff J., Testa J.R. p21-Activated kinase links Rac/Cdc42 signaling to Merlin. J. Biol. Chem. 2002, 277:883-886.
72. Rong R., Surace E.I., Haipek C.A., Gutmann D.H., Ye K. Serine 518 phosphorylation modulates Merlin intramolecular association and binding to critical effectors important for NF2 growth suppression. Oncogene 2004, 23:8447-8454.
73. Thaxton C., Lopera J., Bott M., Fernandez-Valle C. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways. Oncogene 2008, 27:2705-2715.
74. Gutmann D.H., Geist R.T., Xu H., Kim J.S., Saporito-Irwin S. Defects in neurofibromatosis 2 protein function can arise at multiple levels. Hum. Mol. Genet. 1998, 7:335-345.
75. Tang X., Jang S.W., Wang X., Liu Z., Bahr S.M., Sun S.Y., Brat D., Gutmann D.H., Ye K. Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation. Nat. Cell Biol. 2007, 9:1199-1207.
76. Laulajainen M., Muranen T., Nyman T.A., Carpen O., Gronholm M. Multistep phosphorylation by oncogenic kinases enhances the degradation of the NF2 tumor suppressor Merlin. Neoplasia 2011, 13:643-652.
77. Shevde L.A., Das S., Clark D.W., Samant R.S. Osteopontin: an effector and an effect of tumor metastasis. Curr. Mol. Med. 2010, 10:71-81.
78. Shevde L.A., Samant R.S., Paik J.C., Metge B.J., Chambers A.F., Casey G., Frost A.R., Welch D.R. Osteopontin knockdown suppresses tumorigenicity of human metastatic breast carcinoma, MDA-MB-435. Clin. Exp. Metastasis 2006, 23:123-133.
79. Rodrigues L.R., Teixeira J.A., Schmitt F.L., Paulsson M., Lindmark-Mansson H. The role of osteopontin in tumor progression and metastasis in breast cancer. Cancer Epidemiol. Biomarkers Prev. 2007, 16:1087-1097.
80. Rudland P.S., Platt-Higgins A., El-Tanani M., De Silva Rudland S., Barraclough R., Winstanley J.H., Howitt R., West C.R. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res. 2002, 62:3417-3427.
81. Kim Y.W., Park Y.K., Lee J., Ko S.W., Yang M.H. Expression of osteopontin and osteonectin in breast cancer. J. Korean Med. Sci. 1998, 13:652-657.
82. Tuck A.B., O'Malley F.P., Singhal H., Harris J.F., Tonkin K.S., Kerkvliet N., Saad Z., Doig G.S., Chambers A.F. Osteopontin expression in a group of lymph node negative breast cancer patients. Int. J. Cancer 1998, 79:502-508.
83. Lund S.A., Giachelli C.M., Scatena M. The role of osteopontin in inflammatory processes. J. Cell Commun. Signal. 2009, 3:311-322.
84. Kitagawa K., Kotake Y., Kitagawa M. Ubiquitin-mediated control of oncogene and tumor suppressor gene products. Cancer Sci. 2009, 100:1374-1381.
85. Hu R., Peng G., Dai H., Breuer E.K., Stemke-Hale K., Li K., Gonzalez-Angulo A.M., Mills G.B., Lin S.Y. ZNF668 functions as a tumor suppressor by regulating p53 stability and function in breast cancer. Cancer Res. 2011, 71:6524-6534.
86. Rho S.B., Lee J.H., Park M.S., Byun H.J., Kang S., Seo S.S., Kim J.Y., Park S.Y. Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 2011, 585:29-35.
87. Ho K.C., Zhou Z., She Y.M., Chun A., Cyr T.D., Yang X. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability [corrected]. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:4870-4875.
88. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat. Rev. Drug Discov. 2005, 4:988-1004.
89. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
90. Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., Carey M., Hu Z., Guan Y., Sahin A., Symmans W.F., Pusztai L., Nolden L.K., Horlings H., Berns K., Hung M.C., van de Vijver M.J., Valero V., Gray J.W., Bernards R., Mills G.B., Hennessy B.T. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008, 68:6084-6091.
91. Yim E.K., Peng G., Dai H., Hu R., Li K., Lu Y., Mills G.B., Meric-Bernstam F., Hennessy B.T., Craven R.J., Lin S.Y. Rak functions as a tumor suppressor by regulating PTEN protein stability and function. Cancer Cell 2009, 15:304-314.
92. Okahara F., Ikawa H., Kanaho Y., Maehama T. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J. Biol. Chem. 2004, 279:45300-45303.
93. Torres J., Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J. Biol. Chem. 2001, 276:993-998.
94. Aghajanian C., Soignet S., Dizon D.S., Pien C.S., Adams J., Elliott P.J., Sabbatini P., Miller V., Hensley M.L., Pezzulli S., Canales C., Daud A., Spriggs D.R. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin. Cancer Res. 2002, 8:2505-2511.
95. Blaney S.M., Bernstein M., Neville K., Ginsberg J., Kitchen B., Horton T., Berg S.L., Krailo M., Adamson P.C. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J. Clin. Oncol. 2004, 22:4804-4809.
96. Orlowski R.Z., Stinchcombe T.E., Mitchell B.S., Shea T.C., Baldwin A.S., Stahl S., Adams J., Esseltine D.L., Elliott P.J., Pien C.S., Guerciolini R., Anderson J.K., Depcik-Smith N.D., Bhagat R., Lehman M.J., Novick S.C., O'Connor O.A., Soignet S.L. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J. Clin. Oncol. 2002, 20:4420-4427.
97. Richardson P.G., Sonneveld P., Schuster M.W., Irwin D., Stadtmauer E.A., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., San-Miguel J.F., Blade J., Boccadoro M., Cavenagh J., Dalton W.S., Boral A.L., Esseltine D.L., Porter J.B., Schenkein D., Anderson K.C. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 2005, 352:2487-2498.
98. Richardson P.G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., Harousseau J.L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., Miguel J.S., Blade J., Boccadoro M., Cavenagh J., Alsina M., Rajkumar S.V., Lacy M., Jakubowiak A., Dalton W., Boral A., Esseltine D.L., Schenkein D., Anderson K.C. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007, 110:3557-3560.
99. Messersmith W.A., Baker S.D., Lassiter L., Sullivan R.A., Dinh K., Almuete V.I., Wright J.J., Donehower R.C., Carducci M.A., Armstrong D.K. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 2006, 12:1270-1275.
100. Orlowski R.Z., Voorhees P.M., Garcia R.A., Hall M.D., Kudrik F.J., Allred T., Johri A.R., Jones P.E., Ivanova A., Van Deventer H.W., Gabriel D.A., Shea T.C., Mitchell B.S., Adams J., Esseltine D.L., Trehu E.G., Green M., Lehman M.J., Natoli S., Collins J.M., Lindley C.M., Dees E.C. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
101. Aghajanian C., Dizon D.S., Sabbatini P., Raizer J.J., Dupont J., Spriggs D.R. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J. Clin. Oncol. 2005, 23:5943-5949.
102. Irvin W.J., Orlowski R.Z., Chiu W.K., Carey L.A., Collichio F.A., Bernard P.S., Stijleman I.J., Perou C., Ivanova A., Dees E.C. Phase II study of bortezomib and pegylated liposomal doxorubicin in the treatment of metastatic breast cancer. Clin. Breast Cancer 2010, 10:465-470.
103. Trinh X.B., Sas L., Van Laere S.J., Prove A., Deleu I., Rasschaert M., Van de Velde H., Vinken P., Vermeulen P.B., Van Dam P.A., Wojtasik A., De Mesmaeker P., Tjalma W.A., Dirix L.Y. A phase II study of the combination of endocrine treatment and bortezomib. Oncol. Rep. 2012, 27:657-663.
104. Ammoun S., Flaiz C., Ristic N., Schuldt J., Hanemann C.O. Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma. Cancer Res. 2008, 68:5236-5245.
105. Hilton D.A., Ristic N., Hanemann C.O. Activation of ERK, AKT and JNK signalling pathways in human schwannomas in situ. Histopathology 2009, 55:744-749.
106. Garrett C.R., Coppola D., Wenham R.M., Cubitt C.L., Neuger A.M., Frost T.J., Lush R.M., Sullivan D.M., Cheng J.Q., Sebti S.M. Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT. Invest. New Drugs 2011, 29:1381-1389.
107. Yang L., Dan H.C., Sun M., Liu Q., Sun X.M., Feldman R.I., Hamilton A.D., Polokoff M., Nicosia S.V., Herlyn M., Sebti S.M., Cheng J.Q. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004, 64:4394-4399.
108. Hennessy B.T., Lu Y., Poradosu E., Yu Q., Yu S., Hall H., Carey M.S., Ravoori M., Gonzalez-Angulo A.M., Birch R., Henderson I.C., Kundra V., Mills G.B. Pharmacodynamic markers of perifosine efficacy. Clin. Cancer Res. 2007, 13:7421-7431.